Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment

View ORCID ProfileEric B. Dammer, Anantharaman Shantaraman, Lingyan Ping, Duc M. Duong, Ekaterina S. Gerasimov, Suda Parimala Ravindran, Valborg Gudmundsdottir, Elisabet A. Frick, Gabriela T. Gomez, Keenan A. Walker, Valur Emilsson, Lori L. Jennings, Vilmundur Gudnason, Daniel Western, Carlos Cruchaga, James J. Lah, Thomas S. Wingo, Aliza P. Wingo, Nicholas T. Seyfried, Allan I. Levey, View ORCID ProfileErik C.B. Johnson
doi: https://doi.org/10.1101/2023.10.29.23297651
Eric B. Dammer
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
3Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric B. Dammer
Anantharaman Shantaraman
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingyan Ping
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
3Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duc M. Duong
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
3Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ekaterina S. Gerasimov
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suda Parimala Ravindran
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valborg Gudmundsdottir
4Icelandic Heart Association, Kopavogur, Iceland
5Faculty of Medicine, University of Iceland, Reykjavik, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabet A. Frick
4Icelandic Heart Association, Kopavogur, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriela T. Gomez
6Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keenan A. Walker
7Laboratory of Behavioral Neuroscience, National Institute on Aging, Intramural Research Program, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valur Emilsson
4Icelandic Heart Association, Kopavogur, Iceland
5Faculty of Medicine, University of Iceland, Reykjavik, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori L. Jennings
8Novartis Biomedical Research, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vilmundur Gudnason
4Icelandic Heart Association, Kopavogur, Iceland
5Faculty of Medicine, University of Iceland, Reykjavik, Iceland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Western
9Department of Psychiatry, Washington University, St. Louis, MO, USA
10NeuroGenomics and Informatics, Washington University, St. Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Cruchaga
9Department of Psychiatry, Washington University, St. Louis, MO, USA
10NeuroGenomics and Informatics, Washington University, St. Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James J. Lah
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas S. Wingo
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
11Department of Genetics, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aliza P. Wingo
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
12Department of Psychiatry, Emory University School of Medicine, Atlanta, GA, USA
13Division of Mental Health, Atlanta VA Medical Center, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas T. Seyfried
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
3Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allan I. Levey
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik C.B. Johnson
1Goizueta Alzheimer’s Disease Research Center, Emory University School of Medicine, Atlanta, GA, USA
2Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erik C.B. Johnson
  • For correspondence: erik.johnson{at}emory.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Alzheimer’s disease (AD) is currently defined at the research level by the aggregation of amyloid-β (Aβ) and tau proteins in brain. While biofluid biomarkers are available to measure Aβ and tau pathology, few biomarkers are available to measure the complex pathophysiology that is associated with these two cardinal neuropathologies. Here we describe the proteomic landscape of cerebrospinal fluid (CSF) changes associated with Aβ and tau pathology in 300 individuals as assessed by two different proteomic technologies—tandem mass tag (TMT) mass spectrometry and SomaScan. Harmonization and integration of both data types allowed for generation of a robust protein co-expression network consisting of 34 modules derived from 5242 protein measurements, including disease-relevant modules associated with autophagy, ubiquitination, endocytosis, and glycolysis. Three modules strongly associated with the apolipoprotein E ε4 (APOE ε4) AD risk genotype mapped to oxidant detoxification, mitogen associated protein kinase (MAPK) signaling, neddylation, and mitochondrial biology, and overlapped with a previously described lipoprotein module in serum. Neddylation and oxidant detoxification/MAPK signaling modules had a negative association with APOE ε4 whereas the mitochondrion module had a positive association with APOE ε4. The directions of association were consistent between CSF and blood in two independent longitudinal cohorts, and altered levels of all three modules in blood were associated with dementia over 20 years prior to diagnosis. Dual-proteomic platform analysis of CSF samples from an AD phase 2 clinical trial of atomoxetine (ATX) demonstrated that abnormal elevations in the glycolysis CSF module—the network module most strongly correlated to cognitive function—were reduced by ATX treatment. Individuals who had more severe glycolytic changes at baseline responded better to ATX. Clustering of individuals based on their CSF proteomic network profiles revealed ten groups that did not cleanly stratify by Aβ and tau status, underscoring the heterogeneity of pathological changes not fully reflected by Aβ and tau. AD biofluid proteomics holds promise for the development of biomarkers that reflect diverse pathologies for use in clinical trials and precision medicine.

Competing Interest Statement

The AGES-Reykjavik proteomics measurements were supported by Novartis Biomedical Research and performed at SomaLogic. L.L.J is an employee and stockholder of Novartis.

Funding Statement

This study was supported by K08AG068604 (E.C.B.J.), the Emory Goizueta Alzheimer's Disease Research Center (P30AG066511, A.I.L.), the Emory Healthy Brain Study (R01AG070937, J.J.L.), the Accelerating Medicines Partnership Program for Alzheimer's Disease (U01AG061357, A.I.L. and N.T.S.), R01AG072120 (A.P.W. and T.S.W.), and R01AG075827 (T.S.W. and A.P.W.). The AGES-Reykjavik study was financed by National Institute on Aging (NIA) contracts N01-AG-12100 and HHSN271201200022C for Vi.G. Icelandic Heart Association (IHA) received a grant from Althingi (the Icelandic Parliament) and Vi.G. received funding from the NIA (1R01AG065596-01A1).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The IRB of Emory University gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • edammer{at}emory.edu, anantharaman.shantaraman{at}emory.edu, lingyan.ping{at}emory.edu, dduong{at}emory.edu, ekaterina.sergeevna.gerasimov{at}emory.edu, suda.parimala.ravindran{at}emory.edu, valborg{at}hjarta.is, elisabet{at}hjarta.is, ggomez6{at}jhu.edu, keenan.walker{at}nih.gov, valur{at}hjarta.is, lori.jennings{at}novartis.com, v.gudnason{at}hjarta.is, d.e.western{at}wustl.edu, cruchagac{at}wustl.edu, jlah{at}emory.edu, thomas.wingo{at}emory.edu, aliza.wingo{at}emory.edu, nseyfri{at}emory.edu, alevey{at}emory.edu

Data Availability

Raw data, case traits, and analyses related to this manuscript are available at https://www.synapse.org/Emory300ATX.

https://www.synapse.org/Emory300ATX

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 30, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment
Eric B. Dammer, Anantharaman Shantaraman, Lingyan Ping, Duc M. Duong, Ekaterina S. Gerasimov, Suda Parimala Ravindran, Valborg Gudmundsdottir, Elisabet A. Frick, Gabriela T. Gomez, Keenan A. Walker, Valur Emilsson, Lori L. Jennings, Vilmundur Gudnason, Daniel Western, Carlos Cruchaga, James J. Lah, Thomas S. Wingo, Aliza P. Wingo, Nicholas T. Seyfried, Allan I. Levey, Erik C.B. Johnson
medRxiv 2023.10.29.23297651; doi: https://doi.org/10.1101/2023.10.29.23297651
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment
Eric B. Dammer, Anantharaman Shantaraman, Lingyan Ping, Duc M. Duong, Ekaterina S. Gerasimov, Suda Parimala Ravindran, Valborg Gudmundsdottir, Elisabet A. Frick, Gabriela T. Gomez, Keenan A. Walker, Valur Emilsson, Lori L. Jennings, Vilmundur Gudnason, Daniel Western, Carlos Cruchaga, James J. Lah, Thomas S. Wingo, Aliza P. Wingo, Nicholas T. Seyfried, Allan I. Levey, Erik C.B. Johnson
medRxiv 2023.10.29.23297651; doi: https://doi.org/10.1101/2023.10.29.23297651

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)